UnknownPhase 2NCT02968927
TB Host Directed Therapy
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Aurum Institute NPC
- Principal Investigator
- Robert S Wallis, MD,FIDSAThe Aurum Institute NPC
- Intervention
- Everolimus 0.5 MG(drug)
- Enrollment
- 200 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2016 – 2020
Study locations (1)
- The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02968927 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE3NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University
- ACTIVE NOT RECRUITINGPHASE3NCT06649721Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortHuashan Hospital
- RECRUITINGPHASE4NCT06476210The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)Beijing Chest Hospital